Publications

Development and Evaluation of Monoclonal Antibodies against Phosphatidylethanolamine Binding Protein 1 in Pancreatic Cancer Patients

Wang, X., et al., 362, 151-160, J Immunological Methods, 2010

Phosphatidylethanolamine binding protein 1 (PEBP1) is considered to be a prognostic marker in prostate and other cancers. The authors expressed PEBP1 in E. coli and generated a panel of anti-PEBP1 antibodies using hybdridoma technology. The Octet system was used to measure the affinities of antibodies directly from hybridoma supes to PEBP1 to identify antibodies with the highest binding affinities. The authors next identified an optimal antibody binding pair for PEBP1 by performing a sandwich assay on the Octet system. In short, the Octet system enabled screening of antibodies to develop a sensitive immunoassay assay for the cancer biomarker PEBP1.

Read More